Article info
PDFEditorial
Challenge to levetiracetam’s de facto position as generic first-line antiseizure medication
- Correspondence to Dr Aidan Neligan, Neurology, Homerton University Hospital, London, UK; a.neligan{at}ucl.ac.uk
Citation
Challenge to levetiracetam’s de facto position as generic first-line antiseizure medication
Publication history
- Accepted September 23, 2021
- First published October 5, 2021.
Online issue publication
March 18, 2022
Article Versions
- Previous version (18 March 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- NICE guideline review: Epilepsies in children, young people and adults NG217
- Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for adult convulsive status epilepticus: a multicentre non-inferiority randomised control trial
- Intravenous brivaracetam for the management of refractory focal non-convulsive status epilepticus
- Epilepsy and pregnancy: identifying risks
- Drug treatment of epilepsy in adults
- Levetiracetam monotherapy for treatment of structural epilepsy in dogs: 19 cases (2010–2015)
- The new antiepileptic drugs
- Diagnosis and management of the epilepsies in children: a summary of the partial update of the 2012 NICE epilepsy guideline
- Multicentre observational status-epilepticus registry: protocol for ICTAL
- Should we accept the status quo? Time for new trials in status epilepticus